CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 872 enrolled
Drug / intervention
elagolix +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01620528
NCT01620528Phase 3Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain

AbbVie (prior sponsor, Abbott)·interventional·Posted Jun 15, 2012·Updated Sep 18, 2018

In Brief

A Phase 3 clinical trial evaluating elagolix and placebo for Endometriosis. Completed, enrolled 872 participants.

Detailed Summary

A randomized study evaluating the safety and efficacy of elagolix in the management of moderate to severe endometriosis-associated pain in adult premenopausal female participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndometriosis
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJun 15, 2012
Enrollment StartMay 22, 2012
Primary CompletionNov 14, 2014
Study CompletionSep 28, 2015
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 14.0 years ago

Interventions

elagolixdrug

oral tablet

placeboother

oral tablet